Published in J Infect Dis on April 16, 2002
Population history and natural selection shape patterns of genetic variation in 132 genes. PLoS Biol (2004) 7.11
Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med (2008) 4.57
Murine norovirus: a model system to study norovirus biology and pathogenesis. J Virol (2006) 3.91
Coexistence of multiple genotypes, including newly identified genotypes, in outbreaks of gastroenteritis due to Norovirus in Japan. J Clin Microbiol (2004) 3.85
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol (2005) 3.74
Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens. J Virol (2003) 3.15
Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol (2002) 2.98
Mutations within the P2 domain of norovirus capsid affect binding to human histo-blood group antigens: evidence for a binding pocket. J Virol (2003) 2.82
The P domain of norovirus capsid protein forms dimer and binds to histo-blood group antigen receptors. J Virol (2004) 2.68
Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis (2010) 2.64
Cellular and humoral immunity following Snow Mountain virus challenge. J Virol (2005) 2.59
Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol (2010) 2.53
Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis (2013) 2.50
Evolution of human calicivirus RNA in vivo: accumulation of mutations in the protruding P2 domain of the capsid leads to structural changes and possibly a new phenotype. J Virol (2003) 2.37
Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis (2010) 2.21
Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci U S A (2007) 2.07
Norovirus gastroenteritis, carbohydrate receptors, and animal models. PLoS Pathog (2010) 2.02
A homozygous nonsense mutation (428G-->A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J Virol (2005) 1.93
Norovirus capture with histo-blood group antigens reveals novel virus-ligand interactions. J Virol (2004) 1.80
Noroviral P particle: structure, function and applications in virus-host interaction. Virology (2008) 1.75
Norovirus-host interaction: multi-selections by human histo-blood group antigens. Trends Microbiol (2011) 1.73
Rabbit haemorrhagic disease (RHD) and rabbit haemorrhagic disease virus (RHDV): a review. Vet Res (2012) 1.71
Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol (2009) 1.70
Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. PLoS Pathog (2008) 1.69
Noroviruses distinguish between type 1 and type 2 histo-blood group antigens for binding. J Virol (2008) 1.65
Genetic diversity and histo-blood group antigen interactions of rhesus enteric caliciviruses. J Virol (2010) 1.61
Elucidation of strain-specific interaction of a GII-4 norovirus with HBGA receptors by site-directed mutagenesis study. Virology (2008) 1.54
Structural analysis of histo-blood group antigen binding specificity in a norovirus GII.4 epidemic variant: implications for epochal evolution. J Virol (2011) 1.53
Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J Virol (2009) 1.51
A Unique Human Norovirus Lineage with a Distinct HBGA Binding Interface. PLoS Pathog (2015) 1.49
Comprehensive review of human sapoviruses. Clin Microbiol Rev (2015) 1.48
Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J Virol (2010) 1.46
C-terminal arginine cluster is essential for receptor binding of norovirus capsid protein. J Virol (2006) 1.45
Discovery of a proteinaceous cellular receptor for a norovirus. Science (2016) 1.43
Crystal structures of GII.10 and GII.12 norovirus protruding domains in complex with histo-blood group antigens reveal details for a potential site of vulnerability. J Virol (2011) 1.43
Conservation of carbohydrate binding interfaces: evidence of human HBGA selection in norovirus evolution. PLoS One (2009) 1.42
Norovirus. Clin Microbiol Rev (2015) 1.41
Norwalk virus does not replicate in human macrophages or dendritic cells derived from the peripheral blood of susceptible humans. Virology (2010) 1.40
Noroviruses - State of the Art. Food Environ Virol (2010) 1.39
Protruding domain of capsid protein is necessary and sufficient to determine murine norovirus replication and pathogenesis in vivo. J Virol (2012) 1.34
Norovirus gastroenteritis outbreak with a secretor-independent susceptibility pattern, Sweden. Emerg Infect Dis (2010) 1.32
Prevalence of noroviruses and sapoviruses in swine of various ages determined by reverse transcription-PCR and microwell hybridization assays. J Clin Microbiol (2006) 1.32
Strain-dependent norovirus bioaccumulation in oysters. Appl Environ Microbiol (2011) 1.32
Cytokine and antibody responses in gnotobiotic pigs after infection with human norovirus genogroup II.4 (HS66 strain). J Virol (2007) 1.31
Structural basis for the ABO blood-group dependence of Plasmodium falciparum rosetting. PLoS Pathog (2012) 1.27
Binding patterns of human norovirus-like particles to buccal and intestinal tissues of gnotobiotic pigs in relation to A/H histo-blood group antigen expression. J Virol (2007) 1.27
Junctional adhesion molecule 1 is a functional receptor for feline calicivirus. J Virol (2006) 1.24
Lack of norovirus replication and histo-blood group antigen expression in 3-dimensional intestinal epithelial cells. Emerg Infect Dis (2013) 1.23
Fitting background-selection predictions to levels of nucleotide variation and divergence along the human autosomes. Genome Res (2005) 1.22
A single-amino-acid substitution in the P2 domain of VP1 of murine norovirus is sufficient for escape from antibody neutralization. J Virol (2007) 1.20
Beyond immunohaematology: the role of the ABO blood group in human diseases. Blood Transfus (2013) 1.18
The effects of simvastatin or interferon-α on infectivity of human norovirus using a gnotobiotic pig model for the study of antivirals. PLoS One (2012) 1.18
Characterization of emerging GII.g/GII.12 noroviruses from a gastroenteritis outbreak in the United States in 2010. J Clin Microbiol (2011) 1.18
Genogroup II noroviruses efficiently bind to heparan sulfate proteoglycan associated with the cellular membrane. J Virol (2004) 1.16
Challenges of culturing human norovirus in three-dimensional organoid intestinal cell culture models. PLoS One (2013) 1.15
Porcine enteric caliciviruses: genetic and antigenic relatedness to human caliciviruses, diagnosis and epidemiology. Vaccine (2006) 1.14
Asymptomatic norovirus infection in Mexican children. J Clin Microbiol (2006) 1.13
Bile-salt-stimulated lipase and mucins from milk of 'secretor' mothers inhibit the binding of Norwalk virus capsids to their carbohydrate ligands. Biochem J (2006) 1.11
Critical review of norovirus surrogates in food safety research: rationale for considering volunteer studies. Food Environ Virol (2011) 1.10
Experimental inoculation of juvenile rhesus macaques with primate enteric caliciviruses. PLoS One (2012) 1.10
Factors that explain excretion of enteric pathogens by persons without diarrhea. Clin Infect Dis (2012) 1.09
Structural basis for the recognition of Lewis antigens by genogroup I norovirus. J Virol (2012) 1.09
Prevention and self-treatment of traveler's diarrhea. Clin Microbiol Rev (2006) 1.05
Persistent enteric murine norovirus infection is associated with functionally suboptimal virus-specific CD8 T cell responses. J Virol (2013) 1.05
Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis (2003) 1.04
Host genetic factors affect susceptibility to norovirus infections in Burkina Faso. PLoS One (2013) 1.04
Failure of propagation of human norovirus in intestinal epithelial cells with microvilli grown in three-dimensional cultures. Arch Virol (2013) 1.01
Human norovirus transmission and evolution in a changing world. Nat Rev Microbiol (2016) 1.01
Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus. Nanomedicine (Lond) (2012) 0.99
Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis. J Virol (2013) 0.99
Characterization of blockade antibody responses in GII.2.1976 Snow Mountain virus-infected subjects. J Virol (2013) 0.98
Glycosphingolipids as receptors for non-enveloped viruses. Viruses (2010) 0.98
The carbohydrate moiety and high molecular weight carrier of histo-blood group antigens are both required for norovirus-receptor recognition. Glycoconj J (2009) 0.95
Internalization and dissemination of human norovirus and animal caliciviruses in hydroponically grown romaine lettuce. Appl Environ Microbiol (2012) 0.94
Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients. Biol Blood Marrow Transplant (2012) 0.93
Risk factors for infections with Norovirus gastrointestinal illness in Switzerland. Eur J Clin Microbiol Infect Dis (2005) 0.92
Library screen for inhibitors targeting norovirus binding to histo-blood group antigen receptors. Antimicrob Agents Chemother (2006) 0.92
Human sapovirus in clams, Japan. Emerg Infect Dis (2007) 0.91
Epidemiologic Association Between FUT2 Secretor Status and Severe Rotavirus Gastroenteritis in Children in the United States. JAMA Pediatr (2015) 0.91
Norovirus binding to intestinal epithelial cells is independent of histo-blood group antigens. PLoS One (2013) 0.91
Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age. J Gen Virol (2013) 0.91
Gangliosides are ligands for human noroviruses. J Am Chem Soc (2014) 0.90
Correlates of Protection against Norovirus Infection and Disease-Where Are We Now, Where Do We Go? PLoS Pathog (2016) 0.90
Two gastroenteritis outbreaks caused by GII Noroviruses: host susceptibility and HBGA phenotypes. PLoS One (2013) 0.89
The role of type I interferons in intestinal infection, homeostasis, and inflammation. Immunol Rev (2014) 0.89
Histo-blood group antigen assay for detecting noroviruses in water. Appl Environ Microbiol (2008) 0.88
High-pressure inactivation of human norovirus virus-like particles provides evidence that the capsid of human norovirus is highly pressure resistant. Appl Environ Microbiol (2012) 0.88
Blood Groups in Infection and Host Susceptibility. Clin Microbiol Rev (2015) 0.88
Norovirus infections in asymptomatic food handlers in elementary schools without norovirus outbreaks in some regions of Incheon, Korea. J Korean Med Sci (2011) 0.87
Seroprevalence of antibodies against noroviruses among students in a Chinese military medical university. J Clin Microbiol (2004) 0.87
Genogroup IV and VI canine noroviruses interact with histo-blood group antigens. J Virol (2014) 0.87
New Developments in Traveler's Diarrhea. Gastroenterol Hepatol (N Y) (2011) 0.86
Structural analysis of determinants of histo-blood group antigen binding specificity in genogroup I noroviruses. J Virol (2014) 0.86
Structural basis of glycan interaction in gastroenteric viral pathogens. Curr Opin Virol (2014) 0.85
Structural analysis of a rabbit hemorrhagic disease virus binding to histo-blood group antigens. J Virol (2014) 0.84
Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives. Future Virol (2015) 0.82
Functional receptor molecules CD300lf and CD300ld within the CD300 family enable murine noroviruses to infect cells. Proc Natl Acad Sci U S A (2016) 0.81
With a Little Help from my Enteric Microbial Friends. Front Med (Lausanne) (2015) 0.81
Affinities of human histo-blood group antigens for norovirus capsid protein complexes. Glycobiology (2014) 0.81
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
Traces of human migrations in Helicobacter pylori populations. Science (2003) 11.92
Norovirus gastroenteritis. N Engl J Med (2009) 7.66
Laboratory efforts to cultivate noroviruses. J Gen Virol (2004) 4.41
Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch Virol (2011) 3.87
Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med (2002) 3.86
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Norwalk virus shedding after experimental human infection. Emerg Infect Dis (2008) 3.70
Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol (2005) 3.34
Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology (2002) 3.27
Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens. J Virol (2003) 3.15
The peopling of the Pacific from a bacterial perspective. Science (2009) 3.14
Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol (2012) 2.99
Gastroesophageal reflux among different racial groups in the United States. Gastroenterology (2004) 2.87
Norovirus disease: changing epidemiology and host susceptibility factors. Trends Microbiol (2004) 2.83
Recommendations for the classification of group A rotaviruses using all 11 genomic RNA segments. Arch Virol (2008) 2.77
Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) (2002) 2.75
Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet (2002) 2.71
Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 2.59
Helicobacter pylori in North and South America before Columbus. FEBS Lett (2002) 2.57
Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus. Proc Natl Acad Sci U S A (2008) 2.54
Rotavirus antigenaemia and viraemia: a common event? Lancet (2003) 2.51
Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis (2013) 2.50
The epidemiologic and clinical importance of norovirus infection. Gastroenterol Clin North Am (2006) 2.49
Noroviruses everywhere: has something changed? Curr Opin Infect Dis (2006) 2.44
Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis (2006) 2.43
The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis (2005) 2.43
A report card to grade Helicobacter pylori therapy. Helicobacter (2007) 2.41
The 3' end of Norwalk virus mRNA contains determinants that regulate the expression and stability of the viral capsid protein VP1: a novel function for the VP2 protein. J Virol (2003) 2.38
Structural requirements for the assembly of Norwalk virus-like particles. J Virol (2002) 2.38
Norwalk virus infection associates with secretor status genotyped from sera. J Med Virol (2005) 2.34
Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology (2002) 2.32
Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis (2010) 2.21
Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol (2009) 2.15
X-ray structure of a native calicivirus: structural insights into antigenic diversity and host specificity. Proc Natl Acad Sci U S A (2006) 2.09
Rotaviruses: from pathogenesis to vaccination. Gastroenterology (2009) 2.05
Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med (2011) 2.04
Comparing the Blatchford and pre-endoscopic Rockall score in predicting the need for endoscopic therapy in patients with upper GI hemorrhage. Gastrointest Endosc (2010) 2.04
Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology (2005) 2.03
Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter (2009) 2.02
Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol (2011) 1.98
Gastritis staging in clinical practice: the OLGA staging system. Gut (2006) 1.90
Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol (2003) 1.89
Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect (2005) 1.83
Neonatal infection with G10P[11] rotavirus did not confer protection against subsequent rotavirus infection in a community cohort in Vellore, South India. J Infect Dis (2007) 1.83
Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine (2003) 1.83
Inter- and intragenus structural variations in caliciviruses and their functional implications. J Virol (2004) 1.79
Risk factors for immediate and delayed bleeding associated with endoscopic submucosal dissection of gastric neoplastic lesions. Scand J Gastroenterol (2009) 1.75
NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl J Med (2002) 1.75
Noroviruses: The leading cause of gastroenteritis worldwide. Discov Med (2010) 1.73
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter (2011) 1.73
Discrimination between cases of duodenal ulcer and gastritis on the basis of putative virulence factors of Helicobacter pylori. J Clin Microbiol (2002) 1.72
Evolutionary trace residues in noroviruses: importance in receptor binding, antigenicity, virion assembly, and strain diversity. J Virol (2005) 1.71
Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol (2010) 1.69
Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer (2002) 1.69
Biliary stenting in the management of large or multiple common bile duct stones. Gastrointest Endosc (2010) 1.68
Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med (2006) 1.68
Norwalk virus RNA is infectious in mammalian cells. J Virol (2007) 1.66
Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigen. Nature (2012) 1.65
Norwalk virus-specific binding to oyster digestive tissues. Emerg Infect Dis (2006) 1.63
Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol (2009) 1.62
Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection. Gastroenterology (2004) 1.59
Helicobacter pylori infection in mice: Role of outer membrane proteins in colonization and inflammation. Gastroenterology (2002) 1.58
Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol (2005) 1.57
Replication and packaging of Norwalk virus RNA in cultured mammalian cells. Proc Natl Acad Sci U S A (2005) 1.56
Endoscopic demonstration of transient small bowel intussusception in a patient with adult celiac disease. Gastrointest Endosc (2003) 1.55
Identification of Genogroup I and Genogroup II broadly reactive epitopes on the norovirus capsid. J Virol (2005) 1.53
Structural analysis of histo-blood group antigen binding specificity in a norovirus GII.4 epidemic variant: implications for epochal evolution. J Virol (2011) 1.53
Comparative study of the epidemiology of rotavirus in children from a community-based birth cohort and a hospital in South India. J Clin Microbiol (2006) 1.51
Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol (2012) 1.51
Aichi virus, norovirus, astrovirus, enterovirus, and rotavirus involved in clinical cases from a French oyster-related gastroenteritis outbreak. J Clin Microbiol (2008) 1.50
Epidemiology of human noroviruses and updates on vaccine development. Curr Opin Gastroenterol (2014) 1.49
Rotavirus architecture at subnanometer resolution. J Virol (2008) 1.48
Horizontal versus familial transmission of Helicobacter pylori. PLoS Pathog (2008) 1.48
Helicobacter pylori eradication and change in markers of iron stores among non-iron-deficient children in El Paso, Texas: an etiologic intervention study. J Pediatr Gastroenterol Nutr (2011) 1.47
Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis (2013) 1.46
A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine (2009) 1.44
Helicobacter pylori virulence factors: facts and fantasies. Curr Opin Gastroenterol (2005) 1.44
Seroepidemiology of norovirus-associated travelers' diarrhea. J Travel Med (2014) 1.43
Rotavirus viremia and extraintestinal viral infection in the neonatal rat model. J Virol (2006) 1.43
Etest for metronidazole susceptibility in H. pylori: use of the wrong standard may have led to the wrong conclusion. Am J Gastroenterol (2004) 1.43
Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med (2010) 1.43
Initial interaction of rotavirus strains with N-acetylneuraminic (sialic) acid residues on the cell surface correlates with VP4 genotype, not species of origin. J Virol (2002) 1.42
Effect of the carbonic anhydrase inhibitor, acetazolamide, on Helicobacter pylori infection in vivo: a pilot study. Helicobacter (2005) 1.42